It was designated by the FDA as a breakthrough therapy in February 2016 based on early clinical data from a Phase I trial for treating patients with metastatic urothelial bladder cancer whose tumour cells express PD-L1 and who had advanced disease during or after one standard platinum-containing chemotherapy regimen [70]. Here, CD274 is linked to neoplasm.